Tryvio (aprocitentan) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of resistant hypertension (ICD-10: I1A.0)
• prescriber attests that the member is adherent to currently prescribed antihypertensive medications
• member has experienced therapeutic failure, intolerance, or contraindication to maximally tolerated doses of all of the following: thiazide diuretic (e.g. hydrochlorothiazide, chlorthalidone) AND ACE or ARB (e.g. lisinopril, losartan) AND calcium channel blocker (e.g. amlodipine) AND mineralocorticoid receptor antagonist (spironolactone or eplerenone)

Reauthorization criteria

• prescriber attests that the member achieved a reduction in blood-pressure from baseline

Approval duration

12 months